Enfortumab Vedotin
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Enfortumab Vedotin: From Urothelial Carcinoma to Leprosy
One-Sentence Summary
Enfortumab vedotin is an antibody-drug conjugate (ADC) that targets Nectin-4-expressing tumour cells, used mainly in advanced urothelial carcinoma. The TxGNN model’s top prediction for this drug is Leprosy, but this candidate is supported by 0 clinical trials and 0 publications, and the mechanistic rationale itself flags the prediction as likely embedding-similarity noise rather than a genuine biological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this evidence pack (no Taiwan licenses on file); background mechanistic notes describe use in Nectin-4-high urothelial carcinoma |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| US Market Status | Not marketed (Taiwan: 未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for enfortumab vedotin is currently a data gap (DG002, High severity) in this evidence pack. Based on the mechanistic notes attached to this candidate, enfortumab vedotin is an ADC combining an anti-Nectin-4 monoclonal antibody with MMAE, a microtubule inhibitor payload; it kills Nectin-4-high-expressing cells, a profile seen predominantly in urothelial cancer.
Leprosy (Hansen’s disease) is a chronic mycobacterial infection driven by Mycobacterium leprae and host granulomatous/immune pathology — a disease biology entirely unrelated to Nectin-4 expression or microtubule-dependent cell killing. The evidence pack’s own rationale is explicit on this point: there is no known mechanistic relationship between the drug’s ADC/cytotoxic mode of action and leprosy pathophysiology, and the TxGNN score is assessed as most likely reflecting embedding similarity noise rather than a real pharmacological signal.
No clinical trials, literature, or regulatory precedent support this pairing. Given the absence of any corroborating evidence and a rationale that itself argues against biological plausibility, this candidate should not be interpreted as a credible repurposing signal at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No Taiwan (TFDA) authorizations are on file for this drug — 0 licenses recorded, market status “未上市” (not marketed).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (Antibody-drug conjugate; MMAE microtubule-inhibitor payload) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Cytotoxic ADC — standard hazardous drug handling precautions expected, pending confirmation from official labeling |
Safety Considerations
Please refer to the package insert for safety information. TFDA label warnings/contraindications and DDI data are currently unavailable (DG001, Blocking severity — required before any S1 safety pre-assessment can proceed).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (leprosy) has no clinical, literature, or regulatory support, and the attached mechanistic rationale itself concludes there is no plausible biological link between the drug’s ADC/cytotoxic mechanism and the predicted indication — most consistent with model noise rather than a genuine repurposing signal.
To proceed, the following is needed:
- TFDA label (warnings/contraindications) to close the Blocking data gap (DG001)
- Confirmed mechanism-of-action data from DrugBank (DG002)
- A documented original indication/regulatory history for this drug in the target market
- Independent mechanistic or preclinical evidence specifically linking Nectin-4/MMAE biology to leprosy before any further evaluation is warranted
Note: All 9 predicted indications for this drug carry evidence level L5 (no clinical trials, minimal/no literature). Two lower-ranked candidates (malignant catarrh, infectious bovine rhinotracheitis) are veterinary-only conditions, indicating a likely disease-ontology species mismatch in this candidate set — a data-quality signal worth flagging for the broader prediction batch, not just this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.